JPWO2020051356A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020051356A5
JPWO2020051356A5 JP2021512742A JP2021512742A JPWO2020051356A5 JP WO2020051356 A5 JPWO2020051356 A5 JP WO2020051356A5 JP 2021512742 A JP2021512742 A JP 2021512742A JP 2021512742 A JP2021512742 A JP 2021512742A JP WO2020051356 A5 JPWO2020051356 A5 JP WO2020051356A5
Authority
JP
Japan
Prior art keywords
compound
compound according
pharmaceutically acceptable
acceptable salt
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021512742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501327A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/049784 external-priority patent/WO2020051356A1/en
Publication of JP2022501327A publication Critical patent/JP2022501327A/ja
Publication of JPWO2020051356A5 publication Critical patent/JPWO2020051356A5/ja
Pending legal-status Critical Current

Links

JP2021512742A 2018-09-07 2019-09-05 イミダゾキノリン化合物およびその使用 Pending JP2022501327A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728556P 2018-09-07 2018-09-07
US62/728,556 2018-09-07
PCT/US2019/049784 WO2020051356A1 (en) 2018-09-07 2019-09-05 Imidazoquinoline compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2022501327A JP2022501327A (ja) 2022-01-06
JPWO2020051356A5 true JPWO2020051356A5 (sv) 2022-07-04

Family

ID=69722888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512742A Pending JP2022501327A (ja) 2018-09-07 2019-09-05 イミダゾキノリン化合物およびその使用

Country Status (9)

Country Link
US (1) US20210214354A1 (sv)
EP (2) EP4306523A3 (sv)
JP (1) JP2022501327A (sv)
KR (1) KR20210074290A (sv)
CN (1) CN113164460A (sv)
AU (1) AU2019335366A1 (sv)
CA (1) CA3111786A1 (sv)
ES (1) ES2963112T3 (sv)
WO (1) WO2020051356A1 (sv)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015205753A1 (en) 2014-01-10 2016-07-21 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating HER2 positive tumors
CA2954446A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-cd20组合
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
MX2019015744A (es) 2017-06-23 2020-02-20 Birdie Biopharmaceuticals Inc Composiciones farmaceuticas.
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN115916342A (zh) * 2020-07-08 2023-04-04 普渡研究基金会 用于治疗纤维化疾病和癌症的化合物、组合物和方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US689338A (en) * 1901-03-29 1901-12-17 Nat Faucet Company Tapping-bung.
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
BRPI0414045A (pt) * 2003-09-05 2006-10-24 Anadys Pharmaceuticals Inc administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c
CA2580343A1 (en) * 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics, Inc. Imidazoquinoline compounds
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
WO2013033345A1 (en) * 2011-08-30 2013-03-07 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
RS60430B1 (sr) * 2014-04-22 2020-07-31 Hoffmann La Roche Jedinjenja 4-amino-imidazohinolina
CA2954446A1 (en) * 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN112546231A (zh) * 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
CN115350279A (zh) * 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合

Similar Documents

Publication Publication Date Title
JP2020507589A5 (sv)
JP2020125349A5 (sv)
JP2022031403A5 (sv)
JP2021063088A5 (sv)
JPWO2020051356A5 (sv)
JP3479068B2 (ja) 5−フルオロ−2’−デオキシ−3’−チアシチジンのb型肝炎治療への使用
JP2021100937A5 (sv)
JP2019511483A5 (sv)
JP2009507909A5 (sv)
JP2020532532A5 (sv)
JP2012529486A5 (sv)
JP2006523216A5 (sv)
JP2021152063A5 (sv)
JPH11512083A (ja) C型肝炎の治療における1,3−オキサチオランヌクレオシドアナログ
JP2015536986A5 (sv)
JP2005508337A5 (sv)
TWI609015B (zh) 5-Hydroxyindan derivatives containing heterocyclic rings and uses thereof
JP2021102643A5 (sv)
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3
JP2022169780A5 (sv)
JP2020534300A5 (sv)
JPWO2020037091A5 (sv)
JP2006500372A5 (sv)
JPWO2020037092A5 (sv)
RU2005115102A (ru) Новые противоопухолевые соединения